Description
Do you know the identities of the companies developing CAR-T therapies worldwide?
CAR-T companies are on the rise, supported by growing investment flowing into CAR-T product development and landmark approvals of CAR-T cell therapies by the U.S. FDA, European Medicines Agency (EMA), Health Canada, Australian TGA, and others. There have also been major acquisitions within the CAR-T space, with Celgene snagging Juno Therapeutics for a shocking $9 billion in and Gilead acquiring Kite Pharma for an astounding $11.9 billion.
This is a global database of chimeric antigen receptor T-cell therapy (CAR-T) companies that we originally developed for our own purposes.
Because more and more of our readers have been requesting access to it, we are making it accessible to the public for a limited-time only.
Features of the CAR-T Company Database
Chimeric antigen receptors (CARs) are genetically engineered allogeneic cells that are developed in the laboratory and infused into a patient, to help in detecting and fighting cancer cells. The protein constructs stimulate anti-cancer T-cells which in turn boost a patient’s immune system.
The database features the following information for CAR-T market competitors:
- Company Name
- CAR-T Technology
- Disease Targets
- Description of CAR-T Involvement
- Country
- City / State
- Link to CAR-T Programs
- Company Website
Use it to:
- Identify global competitors within the CAR-T marketplace
- Quantify CAR-T products in late-stage development
- Reveal preclinical & clinical programs supporting CAR-T development
- Identify regions that are “hotspots” for CAR-T companies
- Understand partnerships and co-development programs for CAR-T technologies
- Identify M&A activity within the CAR-T industry
Creating the CAR-T Company Database
It took our team of analysts hours of exhaustive research to uncover these CAR-T cell therapy companies from across the globe. It also required translating company sites and clinical trial programs from more than two dozen different languages. Thankfully, we have a talented and multilingual team who was up to the task.
Because we continuously update this database to reflect new competitors entering the CAR-T cell therapy marketplace, it will be an invaluable resource to your group.
Summary
With the value of recent CAR-T IPO’s totaling nearly $1 billion, CAR-T financing rounds exceeding $950 million, and $20 billion of market capitalization from CAR-T companies within the past year, this is clearly a hot market segment.
Would you benefit from knowing the identities of CAR-T market competitors worldwide? Would you also benefit from being informed about these historic funding events?
For a limited-time, you can claim this database for only $49 AND get the “CAR-T Funding Brief” for FREE (a $49 value).
Claim it now and get immediate access to this searchable, sortable Excel spreadsheet.
Both products will immediately be available for download when you checkout below, with printing rights allowed.
Of course, your investment is backed by our 60-Day Money Back Guarantee.
